


Indomethacin

Cat. No.:	HY-14397
CAS No.:	53-86-1
Molecular Formula:	C ₁₉ H ₁₆ ClNO ₄
Molecular Weight:	357.79
Target:	COX; Antibiotic; Influenza Virus; Bacterial
Pathway:	Immunology/Inflammation; Anti-infection
Storage:	4°C, protect from light * In solvent : -80°C, 1 years; -20°C, 6 months (protect from light)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (279.49 mM; Need ultrasonic)
Ethanol : 12.5 mg/mL (34.94 mM; Need ultrasonic)
H₂O : < 0.1 mg/mL (insoluble)

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	2.7949 mL	13.9747 mL	27.9494 mL
	5 mM	0.5590 mL	2.7949 mL	5.5899 mL
	10 mM	0.2795 mL	1.3975 mL	2.7949 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.08 mg/mL (5.81 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (5.81 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.08 mg/mL (5.81 mM); Clear solution
- Add each solvent one by one: 10% EtOH >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 1.25 mg/mL (3.49 mM); Clear solution
- Add each solvent one by one: 10% EtOH >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 1.25 mg/mL (3.49 mM); Clear solution
- Add each solvent one by one: 10% EtOH >> 90% corn oil
Solubility: ≥ 1.25 mg/mL (3.49 mM); Clear solution

BIOLOGICAL ACTIVITY

Description	Indomethacin (Indometacin) is a potent, orally active COX1/2 inhibitor with IC ₅₀ values of 18 nM and 26 nM for COX-1 and COX-2, respectively. Indomethacin has anticancer activity and anti-infective activity. Indomethacin can be used for cancer, inflammation and viral infection research ^{[1][2][3]} .																	
IC₅₀ & Target	Human COX-1 18 nM (IC ₅₀ , in CHO cells)	Human COX-2 26 nM (IC ₅₀ , in CHO cells)																
In Vitro	<p>Indomethacin (Indometacin) (0-150 μM; 24 hours; 3LL-D122 cells) has anticancer activity in vitro^[2].</p> <p>Indomethacin (Indometacin) (0-1000 μM) protects the host cells from damage caused by the virus through activates PKR, resulting in eIF2α phosphorylation, and in turn shutting of translation of viral protein and inhibiting replication of the virus (IC₅₀=2μM)^[3].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay^[2]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>3LL-D122 cells (highly metastatic variant of mouse LLCarcinoma cells)</td> </tr> <tr> <td>Concentration:</td> <td>0, 20, 50, 100 and 150μM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 hours</td> </tr> <tr> <td>Result:</td> <td>Inhibited cell viability at 20 mM, with 50% inhibition at 60 mM.</td> </tr> </table> <p>Cell Viability Assay^[2]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>3LL-D122 cells (highly metastatic variant of mouse LLCarcinoma cells)</td> </tr> <tr> <td>Concentration:</td> <td>0, 30 and 80μM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 hours</td> </tr> <tr> <td>Result:</td> <td>Decreased in the percentage of cells at the G2/M phase and increased in the percentage of cells at G1 phase.</td> </tr> </table>		Cell Line:	3LL-D122 cells (highly metastatic variant of mouse LLCarcinoma cells)	Concentration:	0, 20, 50, 100 and 150μM	Incubation Time:	24 hours	Result:	Inhibited cell viability at 20 mM, with 50% inhibition at 60 mM.	Cell Line:	3LL-D122 cells (highly metastatic variant of mouse LLCarcinoma cells)	Concentration:	0, 30 and 80μM	Incubation Time:	24 hours	Result:	Decreased in the percentage of cells at the G2/M phase and increased in the percentage of cells at G1 phase.
Cell Line:	3LL-D122 cells (highly metastatic variant of mouse LLCarcinoma cells)																	
Concentration:	0, 20, 50, 100 and 150μM																	
Incubation Time:	24 hours																	
Result:	Inhibited cell viability at 20 mM, with 50% inhibition at 60 mM.																	
Cell Line:	3LL-D122 cells (highly metastatic variant of mouse LLCarcinoma cells)																	
Concentration:	0, 30 and 80μM																	
Incubation Time:	24 hours																	
Result:	Decreased in the percentage of cells at the G2/M phase and increased in the percentage of cells at G1 phase.																	
In Vivo	<p>Indomethacin can be used in animal modeling to construct gastrointestinal ulcer models.</p> <p>Indomethacin (Indometacin) (0.01-10 mg/kg; p.o.; for 3 hours; male Sprague-Dawley rats) induces paw oedema and hyperalgesia measurement dose-dependently reversed carrageenan-induced hyperalgesia^[1].</p> <p>Indomethacin (Indometacin) (10 mg/mL; p.o.; daily, for 29 days; male C57BL/6J mice) inhibits tumor growth in vivo^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Male Sprague-Dawley rats^[1]</td> </tr> <tr> <td>Dosage:</td> <td>0.01-10 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Oral administration; for 3 hours</td> </tr> <tr> <td>Result:</td> <td>Inhibited the carrageenan-induced rat paw oedema (ED₅₀=2.0 mg/kg) and hyperalgesia (ED₅₀=1.5 mg/kg) in a dose-dependent manner.</td> </tr> </table> <table border="1"> <tr> <td>Animal Model:</td> <td>Male C57BL/6J mice^[2]</td> </tr> <tr> <td>Dosage:</td> <td>10 mg/mL</td> </tr> <tr> <td>Administration:</td> <td>Oral administration; daily, for 29 days</td> </tr> </table>		Animal Model:	Male Sprague-Dawley rats ^[1]	Dosage:	0.01-10 mg/kg	Administration:	Oral administration; for 3 hours	Result:	Inhibited the carrageenan-induced rat paw oedema (ED ₅₀ =2.0 mg/kg) and hyperalgesia (ED ₅₀ =1.5 mg/kg) in a dose-dependent manner.	Animal Model:	Male C57BL/6J mice ^[2]	Dosage:	10 mg/mL	Administration:	Oral administration; daily, for 29 days		
Animal Model:	Male Sprague-Dawley rats ^[1]																	
Dosage:	0.01-10 mg/kg																	
Administration:	Oral administration; for 3 hours																	
Result:	Inhibited the carrageenan-induced rat paw oedema (ED ₅₀ =2.0 mg/kg) and hyperalgesia (ED ₅₀ =1.5 mg/kg) in a dose-dependent manner.																	
Animal Model:	Male C57BL/6J mice ^[2]																	
Dosage:	10 mg/mL																	
Administration:	Oral administration; daily, for 29 days																	

Result:

Delayed the onset of tumor growth and the initial growth rate of the footpad tumors.

CUSTOMER VALIDATION

- Biomaterials. 16 September 2022.
- Hepatology. 2023 Feb 1;77(2):456-465.
- Clin Transl Med. 2021 Oct;11(10):e548.
- Chem Mater. 2017, 29(19):8221-8238.
- Appl Mater Today. 2023 Apr.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Riendeau D, et, al. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br J Pharmacol. 1997 May;121(1):105-17.
- [2]. Eli Y, et, al. Comparative effects of indomethacin on cell proliferation and cell cycle progression in tumor cells grown in vitro and in vivo. Biochem Pharmacol. 2001 Mar 1;61(5):565-71.
- [3]. Amici C, et, al. Inhibition of viral protein translation by indomethacin in vesicular stomatitis virus infection: role of eIF2 α kinase PKR. Cell Microbiol. 2015 Sep;17(9):1391-404.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA